060) The 5-year survival rates of patients with primary

060). The 5-year survival rates of patients with primary PARP inhibitor & prior history of cGVHD + and primary & prior history of cGVHD – were 64% and 25%, respectively. Discussion Our data showed that allo-HCT resulted in long-term disease remission and an eventual cure of Q VD Oph active leukemia in a subset of de novo AML or ALL patients with marrow blast ≤ 26% and without poor-risk cytogenetics, possibly by graft-versus-leukemia (GVL) effects mediated through cGVHD. A retrospective

study with a large cohort using data reported to the Center for International Blood and Marrow Transplant Research demonstrated that pre-transplant variables delineated subgroups with different long-term allo-HCT outcomes in adult patients with acute leukemia not in remission [9]. However, they did not address the effect of cGVHD on survival. Baron et al. have reported that extensive cGVHD was associated with decreased risk of progression or relapse in patients with AML or MDS in complete remission at the time of nonmyeloablative HCT [16]. However, it remains unclear whether cGVHD is associated with long-term disease control in patients who have active leukemia at transplant.

The results of the current study showed that GVL effects mediated by cGVHD may play a crucial role in long-term survival in or a cure of active leukemia, especially in patients without poor-risk cytogenetics. Selleckchem DMXAA Further study on the possible relationship between cGVHD and GVL effects would be very helpful in the management of immunosuppressive treatment. For patients who were ineligible for myeloablative conditioning due to comorbidities coupled with rapidly progressive leukemia, we administered sequential cytoreductive chemotherapy, followed by reduced-intensity conditioning for allo-HCT in order to reduce toxicity and obtain sufficient anti-leukemic efficacy. The utility of the combination of sequential cytoreductive chemotherapy and reduced-intensity conditioning for allo-HCT was previously reported [17]. Our results did not show that this sequential regimen had an advantage in controlling why active leukemia. However, we speculated that effective tumor

reduction by individual chemotherapy and/or conditioning for allo-HCT to control disease until cGVHD subsequently occurred might also be important, particularly in rapidly proliferating leukemia. In contrast, intensive conditioning did not appear to be essential in relatively indolent leukemia, even with non-remission. Based on our results, CB might be unsuitable as a source of stem cells for treatment of active leukemia at the time of allo-HCT. However, most patients receiving CBT could not wait for an unrelated donor search because their disease tended to be aggressive compared with those in the unrelated BM group. Thus, it is difficult to arrive at any conclusions about the best stem cell source for allo-HCT in patients in non-remission status based solely on our results.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>